Navigation Links
Pendant Biosciences Announces Acceptance into JLABS @ Toronto
Date:4/27/2017

NASHVILLE, Tenn., April 27, 2017 /PRNewswire/ -- Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held advanced materials company developing innovative surface modification and drug delivery technologies, today announced that it has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto.

Shawn Glinter, Founder and Chief Executive Officer of Pendant Biosciences, noted, "We are excited to become part of the JLABS @ Toronto community, and are honored to be the first Tennessee-based company to join this unique and dynamic life science ecosystem. Acceptance into JLABS perfectly complements our existing research and development activities being conducted with our academic collaborator and partner, Christine Allen, Ph.D., Professor and GSK Chair in Pharmaceutics and Drug Delivery at the University of Toronto, and serves to expand our presence in this important life science hub. As an early-stage company, Pendant Biosciences and its team gain immediate access to, and the ability to collaborate with, the Johnson & Johnson Innovation network, industry experts with unparalleled translational research and commercialization experience, as well as key life science investors who can help us drive development of our product candidates."

Alan Bentley, Assistant Vice Chancellor for Vanderbilt Center Technology Transfer & Commercialization, noted, "We are delighted that Pendant Biosciences, which licensed its technology from Vanderbilt University, has been given this exceptional opportunity. The company's increased footprint in Toronto will, no doubt, be invaluable, and we will be watching their continued progress with great interest." 

JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

About Pendant Biosciences
Based in Nashville, TN, Pendant Biosciences is an advanced materials company developing innovative surface coating and drug delivery technologies using a unique, polymer-based platform. The company is initially focused on applications within the orthopedic market, and its lead product candidate is a surface modification intended to reduce the risk of infection associated with certain orthopedic implants. The platform also serves as a product engine with broad utility in multiple therapeutic areas.

Contact at Pendant Biosciences, Inc. At Rx Communications Group, LLCShawn Glinter 

Paula Schwartz                                                  Founder and Chief Executive Officer

Managing Director615-491-3270

917-322-2216shawn@pendantbio.com

pschwartz@rxir.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pendant-biosciences-announces-acceptance-into-jlabs--toronto-300447213.html


'/>"/>
SOURCE Pendant Biosciences, Inc. (formerly Nanoferix, Inc.)
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
2. TOMA Biosciences Releases the COMPASS Tumor Profiling System
3. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
4. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
5. Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors
6. Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
7. DuPont Industrial Biosciences Leader Presents Major Advances in Biomaterials at 2017 Advanced Bioeconomy Leadership Conference
8. Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation
9. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
10. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
11. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, ... it has closed on the purchase of greenfield for a new, expanded manufacturing ... includes over 21 acres in the initial acquisition, with an option to purchase ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering ... 50 million stem cells total, patients may choose which extremities they would like treated. ... joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... combine up to three different materials for use with CRM, neurostimulation, vascular, and ... three materials to meet specific design requirements, performance, and cost criteria; especially where ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... top radiation centers in 16 countries, has reached its 20th anniversary of worldwide ... in routine use at top universities including University of Pennsylvania, University of Michigan, ...
Breaking Biology Technology:
(Date:7/1/2020)... ... 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit research ... adult brain cancer—announced today the appointments of its first Senior Fellows: John Boockvar, ... organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; they ...
(Date:6/28/2020)... ... ... In an upcoming episode scheduled for the fall of 2020, Advancements with Ted ... local listings for more info. , Today, the majority of testing is performed at ... the country. Results are then available several days later. Now, in an effort to ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... services, today announced that the company has received ISO9001:2015 certification for the ... and research industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s commitment ...
Breaking Biology News(10 mins):